Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

autologous multiple antigen-specific T cells MASE-T

A preparation of autologous T cells targeting multiple antigens expressed by melanoma cells, with potential immunomodulating and antineoplastic activities. Peripheral blood T cells from the patient are collected, processed with artificial antigen-presenting scaffolds, and enriched and expanded ex-vivo to generate multiple antigen-specific endogenously-derived T cells (MASE-T) targeting multiple antigens expressed by melanoma cells. Upon administration, the autologous multiple antigen-specific T cells MASE-T are re-introduced into the patient, where they target and kill melanoma cells expressing these specific antigens.
Synonym:MASE-T
MASE-T cells
multiple antigen specific endogenously derived T cells
multiple antigen-specific endogenously-derived T cells
Search NCI's Drug Dictionary